Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
I think once there is excess money being made and debts paid off I am all for spending it all n the 180MWH of storage they propose at both sites.
Today is a positive because how may updates have shown a downgrade over the years. FM is finally finding stability even with load shedding.
The last month has seen the highest declared short positions in THG history.
To wipe out 4.16% will substantially increase the SP, so hopefully any sustained buying pressure on good news has a double whammy effect.
May take time to separate those with patience and lack of fear as in any stock.
I know it's hard being a troll researching the most recent RNS's to learn about a share then to bash it.
However Anne Brindley/NFX already had this idea in the pipeline early 2021. Preliminary studies had already been done in 2021 showing promising results.. If the results weren't promising then they probably wouldn't consider this quickly accepted and cheaper method of research.
https://www.lse.co.uk/rns/NFX/research-results-nn5ek5npkhs2elh.html
Dr Lee Borthwick, Senior Lecturer in Fibrosis Biology at the Newcastle Fibrosis Research Group, Newcastle University, said: "The data from this most recent study of Nuformix's drug candidate, NXP002, are very encouraging in combination with current IPF drugs and show clear attenuation of both fibrosis and inflammatory markers in combination with pirfenidone or nintedanib. This reinforces previous work done in our laboratories on this compound."
Dr Anne Brindley, CEO of Nuformix, said: "IPF is a devastating disease with few treatment options and there is a real need for new therapies that are efficacious but that have better tolerability than the current therapies on the market. IPF is likely to become a combination market in the future. The results of this ex-vivo study in IPF are very encouraging and suggest the potential benefit of using NXP002 in combination with standard of care treatments for IPF. These results underpin NXP002's potential and demonstrate that further development of NXP002 for the treatment of IPF is warranted."
At Faramog I just took it from this portion of the court docs.
‘Among the EHL consortium there was an aspiration to find a way for EHL to become publicly listed, albeit Garnet and Bushveld differed as to the time this should happen. A route for a listing would be to have a SPAC such as Mustang
Page 13
Approved Judgment: Garnet Commerce Ltd v VRFB Holdings Ltd
acquire the issued share capital of EHL in a reverse takeover and IPO of Mustang shares. On 16 September 2020 Mr Mojapelo sent an internal Bushveld email describing such a route. According to Mr Nikomarov other structures involving a Mustang investment were considered as time passed.
55. Meanwhile matters continued with Mustang. On 1 October 2020 Mr Mojapelo sent to Mr Gallegos a document which he described as “the Enerox-Invinity comparison as promised”. This document contained some information which had previously been provided to Mustang and which is not complained of by Garnet, and some which came to be published later. But while the information in itself may be bland, that does resolve the question which I have just referred to. That question I address later.
56. On 8 October 2020 Mr Mojapelo introduced to Mr Otto the reverse takeover and IPO suggestion involving Mustang. This email explained, “We have recently discussed the potential listing of EHL in the shorter term to assist in sourcing the significant additional funding Enerox will require going into 2021 as well as to take advantage of the strong investor interest in energy transition plays.” It went on to explain positive features said to be enjoyed by Mustang and to set out detailed suggestions for the proposed transaction. Mr Otto’s reply was terse: “Fortune, Post conclusion of the JVA and Board ramp up we can discuss when an IPO should be pursued. What is the latest on Bushveld’s missing October payment?”
A young colleague at work mentioned the Myprotein calendar (£75) is a must have every year for the youngsters. They usually get sold out and I see the current young adult generation prefer looking healthy for social media than 18-30's parties and getting sloshed like mine did.
I know the other calendar was mentioned but this one is probably a better money spinner.
This needs a deal like Evgen Pharma announced today. Their M-cap small like NFX and multi-bagged today and potentially a deal like this would get NFX back to dizzy heights.
Thinking out of the box would Russia want to produce V at full capacity, if China and India are the only ones buying and at a cheap price where the profitability might not be ideal and break even at best. We know many miner/producers in industry tend to slow down and ramp up to demand.
Only time will tell and with V prices rising as the signal.